Abbreviations used: CaM, calmodulin; CCA, common carotid ar tery; MCA, middle cerebral artery; PKC, protein kinase C; J1PKC, l' isoform of protein kinase C; J1PKC-KO, J1-protein kinase C knock-out mice; TTC, triphenyltetrozolium chloride.
3 ) in /,PKC-KO than in wild-type (WT) animals (n = 12;
22.6 ± 7.4 mm " ). To control for possible differences related to genetic background, the authors analyzed Balb/cJ, C57BL/6J, During ischemia and reperfusion, increases in intra cellular Ca 2 + occur at least in part in response to excito toxicity (Choi, 1995) . Ca 2 + is an essential second mes senger with a pivotal role in ischemic disease, and Ca 2 + regulates the phosphorylation of many intracellular pro teins (Hanson and Schulman, 1992) . Signal transduction through Ca 2 + is mediated in part by the activation of protein kinases, including protein kinase C (PKC), and protein phosphatases, including Ca 2 +/calmodulin (CaM)-dependent protein phosphatase 2B (calcineurin). Postranslational modification through protein phosphor ylation plays an essential role in regulating various en zymes, ion channels, receptors, and cytoskeletal ele-and 129SYJ WT in the MCA/CCA model of focal ischemia. No significant differences in stroke volume were detected between these WT strains. Impaired substrate phosphorylation as a con sequence of "{PKC-KO might be corrected by inhibition of protein dephosphorylation. To test this possibility, "{PKC-KO mice were treated with the protein phosphatase 2B (calcineu rin) inhibitor, FK-506, before ischemia. FK-506 reduced (P < 0.008) the infarct volume in "{PKC-KO mice (n = 7; 24.6 ± 4.6 mm
3 ), but at this dose in this model, had no effect on the infarct volume in WT mice (n = 7; 20.5 ± 10.7 mm 3 ments (Hanson and Schulman, 1992) . Dysfunctional phosphorylation may, therefore, lead to loss of intracel lular homeostasis and consequent collapse of cell integ rity . A member of the family of serine/threonine kinases, PKC is one of the most important multifunctional protein kinases in the brain. It is implicated in many vital aspects of CNS physiologic function, including synaptic plastic ity, excitability, growth, proliferation, gene expression, and apoptosis (Tanaka and Nishizuka, 1994; Zhang et al., 1995) . Protein kinase C consists of a family of closely related isoforms, most of which are detectable in the brain and are differentially activated by phospholipids and Ca 2 +. In response to cerebral ischemia, the catalytic activity of PKC in brain is greatly inhibited, and the enzyme is proteolyzed (Louis et aI., 1988; Kochhar et aI., 1989; Wieloch et aI., 1991; Aronowski et al., 1992a; Cardell and Wieloch 1993) . The ", isoform of PKC (",PKC) is highly enriched in neurons and is particularly susceptible to proteolytic degradation after ischemia (Huang et aI., 1988; Wieloch et aI., 1991; Zablocka et al., 1998) . Irreversible inactivation and translocation of PKC always precedes neuronal damage, and is blocked by treatments that protect neurons from ischemic damage Aronowski et al., 1992b) , implying a positive correlation between sustained activity of PKC and neuroprotection. On the other hand, Sieber et al. (1998) demonstrated that after global ischemia, expres sion and activity of PKC increases before delayed cell death in brain regions that are most susceptible to isch emic damage. Finally, results suggesting either a protec tive or deleterious role of PKC were obtained when isch emic damage was probed with inhibitors of protein ki nases, staurosporine or 1-(S-isoquinolinesulphonyl)-2methylpiperazine dihydrochloride (H-7), which also affect PKC activity. Hara et al (1990) , injecting animals with staurosporine, observed neuroprotection after global ischemia, whereas Madden et al. (1991) , using stauro sporine or H-7, produced augmentation of ischemic dam age using a model of spinal cord ischemia. There are many reasons for these discrepancies; however, the lack of these inhibitor's efficacy or specificity and different ischemic paradigms may be a factor.
Changes in intracellular Ca 2 + also regulate dephos phorylation of intracellular substrates through activation of a ubiquitous Ca 2 +/CaM-dependent serine/threonine protein phosphatase, calcineurin. Calcineurin' s effects are either by direct dephosphorylation of phosphosub strates or by activation of protein phosphatase 1 in a reaction that involves dephosphorylation of a protein phosphatase 1 inhibitory protein (Klee, 1991; Mulkey et aI., 1994) . An inhibitor of calcineurin, FKS06, has been shown to reduce ischemic damage after global (Drake et aI., 1996) and focal (Sharkey and Butcher., 1994; Butcher et aI., 1997) ischemia, suggesting that calcineu rin substrates could be involved in ischemic disease.
Recently, l'PKC knock-out mice (l'PKC-KO) were used to characterize the role of this enzyme in synaptic plasticity. The l'PKC-KO mice are fully viable, although they display abnormal gaits and mild deficits in spatial and contextual learning when subjected to behavioral testing (Abeliovich et aI., 1993b) . Mutant mice have little detectable difference in baseline synaptic transmission, exhibit normal long-term depression and paired-pulse fa cilitation, although they have diminished long-term po tentiation (Abeliovich et aI., 1993a) .
We hypothesized that decreases in PKC phosphoryla tion resulting from ischemia may cause phosphorylation imbalances in favor of protein dephosphorylation, medi ated at least in part by calcineurin, leading to increased damage. To test this hypothesis, we used l'PKC-KO mice and demonstrated their elevated susceptibility to focal ischemia. Interestingly, the increased damage was reversed by FK-S06 treatment, an inhibitor of calcineurin activity.
METHODS

Animals
The production of mice genetically deficient in the '{ isoform of PKC was described previously (Abeliovich et aI., 1993a) .
Briefly, a homologous recombination vector was constructed containing ,{PKC sequences harboring 2.5 kb deletion. Integra tion of this vector also containing neo resulted in a loss of an exon containing the nucleotide-binding domain required for catalytic activity. The vector was transfected into El4ES cells, and clones containing the desired homologous integration were identified by 041S selection and Southern blot hybridization.
Chimeric males initially were mated to C57BLl6J females and were the same animals used in the study by Abeliovich et al. (1993a,b) . Finally, to improve the efficiency of breeding, mice were back-crossed eight times into the Balb/cJ background.
Homozygous animals were bred to produce offspring ('{PKC KO) that were subjected to the experimental protocols de scribed later. Mice were typed by polymerase chain reaction analysis with a set of primers as described by Abeliovich et al. (1993a) . The average weight of '{PKC-KO mice was IS.S ± 1.4 g. Western blotting of brain extracts with an antibody specific to the '{ isoform of PKC verified the absence of ,{PKC in these animals. Balb/cJ (lS.6 ± 1.5 g), C57BLl61 (lS.7 ± 2.0 g), and I 29SVJ (19.2 ± 1.9 g) were obtained from Jackson Laborato ries and housed in the institutional animal care facility for at least 72 hours before surgery. Both male and female mice were used. Each experimental group was built out of an equal num ber of mice of the same sex. In no group were the differences between males and females greater than I. All animals were kept in a 12: 12-hour light-dark cycle with free access to food and water. All procedures were in compliance with the National Institute of Health guidelines for the humane care of animals.
Focal cerebral ischemia
Unilateral middle cerebral artery (MCA) and common ca rotid artery (CCA) occlusion was performed exactly as de scribed previously (Waxham et aI., 1996) . Briefly, mice starved overnight between 5 and 7 weeks of age were anesthetized with chloral hydrate (0.35 g/kg), the skull was exposed, and a small burr hole was produced over the MCA. A O.003-cm (0.005inch) diameter stainless steel wire (Small Parts, Inc., Miami, FL, U.S.A.) was placed underneath the left MCA rostral to the rhinal fissure, proximal to the major bifurcation of the MCA, and distal to the lenticulostriate arteries. The artery then was lifted and the wire rotated clockwise. The left CCA then was occluded using atraumatic Heifetz aneurysm clips. Reperfusion was established after 150 minutes of occlusion by first remov ing the aneurysm clips from the CCA, then rotating the wire counterclockwise, and removing it from beneath the MeA.
This paradigm resulted in reproducible slightly submaximal infarct volume in our previous studies (Waxham et aI., 1996) . 
Infarct volume measurement
Twenty-four hours after the onset of ischemia, under chloral hydrate anesthesia, mice were perfused with 30 mL of saline through the ascending aorta. The brain was removed, sectioned into 2-mm thick sections, and stained with 2% 2,3,5triphenyltetrazolium chloride (TTC) in phosphate-buffered sa line for 30 minutes at room temperature before fixing in 10% buffered formalin. Morphometric determination of infarct size was achieved using a computer-based image analyzer operated by "Brain" software (Drexel University, Philadelphia, PA, U.S.A.) as previously described (Waxham et a!., 1996) . Infarcts were restricted to cortical tissue. The infarct volume (in cubic millimeters) was calculated from the difference between the volume of contralateral cortex and the volume of the TTC stained portion (nonischemic) of ipsilateral cortex of each mouse. This indirect measure of infarct volume, based on the assumption that the volume of the ipsilateral and contralateral cortex are the same before ischemia, corrects the total infarct volume for the edema component (Swanson et a!., 1990) . Sta tistical significance was determined by analysis of variance and the Newman-Keuls test.
Physiologic parameters
Body temperature in our study was controlled and sustained during ischemia and the initial hour of reperfusion. In a recent report, FK506 at the same dose used in this study (I mg/kg) had no effect on brain and body temperature in experimental stroke in rats (Sharkey and Butcher, 1994; Butcher et aI., 1997 ). In the current study, we did not measure P02, Pc02, pH, and blood pressure. However, recent studies using rats and the same dose of FK506 showed no effect on blood gases, pH, and arterial blood pressure (Sharkey and Butcher, 1994; Butcher et aI., 1997) . Finally, using laser Doppler flowmeter to measure ce rebral perfusion in the core of the infarction before and 15 minutes after ischemia, we did not find statistical cross-strain (including -yPKC-KO) differences or treatment effect on cere bral perfusion (Table I) .
Other methods FK506 (Fujisawa Pharmaceutical, Osaka, Japan) was dis solved in 100% ethanol, then diluted in saline (0.1 % final con centration of ethanol) and administered at I mg/kg in 200 fLL intraperitoneally I hour before vessel occlusion. This dose has been shown to produce protection from damage in the rat model of focal ischemia (Sharkey and Butcher., 1994) . Because of the negligible amount of ethanol (equivalent to 0.2 fLL of 100% ethanol) used during FK-506 injection, we used un treated animals as controls for FK-506.
Western blot analysis was performed on ipsilateral and con tralateral cortex homogenates obtained from Balb/cJ and )'PKC-KO mice as described previously (Waxham et aI., 1996) .
Immunostaining of Western blots, as described previously Both CaM-KII and PKC catalytic activity were assayed us ing 3 fLg of crude brain homogenate protein exactly as de scribed previously (Aronow ski et aI., 1992a) using either synthetic peptide autocamtide-3 (KKALHRQETVDAL) (Aronow ski et aI., 1996) for CaM-KII or peptide NG ( 2 8-43 ) (AAAKIQASFRGHMAR) (Klann et aI., 1998) for PKC.
RESULTS
Genetic background and susceptibility to ischemic damage
Gene knock-out approaches in mice have provided important new tools to investigate the genetic and mo lecular basis of brain damage after ischemia. However, an important concern in interpreting results from this approach is that of background genetic heterogeneity.
This heterogeneity comes from three sources: (l) the embryonic stem cells used for "knocking out" the gene are from 129 mouse; (2) the founder mouse is typically CS7BLl6; and (3) in the case of the current study, the strain used for generating mice for experimental analysis is BALB!C. Despite attempts to minimize heterogeneity by extensive back-crossing into the BALB/cJ strain, eliminating the possibility that the observed differences are caused by heterogeneity from either 129SV or CS7BLl6 genetic carryover is difficult. This is particu larly salient in studies of focal ischemia in mice, since genetic background has been shown to play a significant role in altering the extent of damage after the insult (Bar one et a!., 1993; Fujii et aI.,1997; Maeda et aI., 1999) . To establish a database for the current and future work, we undertook a study to define the extent of damage after focal ischemia in each of the three mouse strains Balb/cJ, CS7BLl6J, and 129/SVJ. Earlier work (Waxham et aI., 1996) showed that ISO minutes of focal ischemia, fol lowed by 21.S hours of reperfusion, produced just sub maximal infarct volume in the wild-type CS7BLl6J strain of mice. A similar protocol was applied to evaluate the contribution of genetic background to infarct volume. These data are summarized in Fig. 1 and show that, overall, there is no statistical difference in infarct volume between the three strains of mice using this protocol. The average infarct volumes were 16.7 ± 4.9 mm 3 , 20.9 ± 6.3 mm 3 , and 22.6 ± 7.4 mm 3 for 129/SVJ, CS7BLl6J, and BALB/cJ, respectively. The infarct volume of commer cially available CS7BLl6J (20.9 ± 6.3 mm 3 ) is nearly identical to wild-type litter mates bred from heterozy gous a-subunit CaM-KII (aCaM-KII) knock-out mice in the CS7BLl6 background (21.9 ± 6.4 mm 3 ) (Wax ham et aI., 1996). Thus, the protocol we use for producing in farcts is consistent, and, overall, the genetic background contributes little to differences in infarct volume under the conditions used in our experiments. analyses were performed using BALB/cJ mice as con trols. As anticipated, probing extracts from BALB/cJ and -yPKC-KO brains, using antibody to -yPKC, we detected an immunopositive band at approximately 87 kd in BALB/cJ, whereas no immunoreactivity was detected in -yPKC-KO animals (Fig. 2) antibody to exCaM-KII and actin showed no difference in the quantity of these proteins between BALB/cJ and -yPKC-KO animals (Fig. 2) . Similar to the results of Abe liovich et al. (1993) , -yPKC-KO brain extracts displayed 74% of PKC activity relative to BALB/cJ. In contrast, there was no difference in CaM-KII activity between -yPKC-KO and BALB/cJ mice (Table 2) .
To assess PKC's role in the pathobiologic mechanism of ischemia, we analyzed the susceptibility of -yPKC-KO animals to damage produced by focal ischemia. Occlu sion of the MCA/CCA in -yPKC-KO mice resulted in infarct volumes of 31.1 ± 4.2 mm 3 (n = 10) ( Figs. 3 and   4 ), which were significantly larger than infarct volumes in BALB/cJ mice 22.6 ± 7.4 mm 3 (n = 12) (P < 0.003) ( Figs. 3 and 4) . In general, the infarct volume between animals was consistent; however, one -yPKC-KO animal developed whole ipsilateral hemisphere infarction (S6.S mm 3 ). This type of infarction has been detected in only 4 of 300 mice subjected to this protocol, and the cause is not clear. We excluded this animal from the analysis to avoid overinflating the average infarct volume in the -yPKC-KO group. We conclude that mice deficient in the -y isoform of PKC exhibit increased damage after focal ischemia.
Selective attenuation of infarct volume in /,PKC-KO animals by FK506
Because reduced PKC activity represents the likely explanation for increased susceptibility to ischemia in -yPKC-KO mice, we explored the possibility that inhibi tion of protein dephosphorylation in these animals might be capable of attenuating their elevated ischemic vulner ability. CaIcineurin is highly enriched in neurons and is postulated to reverse the phosphorylation of numerous PKC substrates, suggesting functional interplay between these two enzymes. To address this issue, the well characterized brain-permeable calcineurin inhibitor FKS06 was used. Treatment of -yPKC-KO mice with FKS06 1 hour before stroke resulted in significant (P < 0.0 I) reductions in infarct volume from 31.1 ± 4.2 (n = 10) to 24.6 ± 4.6 mm 3 (n = 7). Similar treatment of wild-type BALB/cJ mice with FKS06 did not signifi cantly reduce ischemic infarct volume (Fig. 4) . These results indicate that this dose of FK-S06 can preferen tially rescue neurons in mice missing the -y isoform of PKC. We propose that inhibition of calcineurin-mediated dephosphorylation is capable of compensating for im paired phosphorylation in -yPKC-KO mice. These results also suggest that interplay between -yPKC and calcineu rin activity regulate ischemic vulnerability.
DISCUSSION
In the current study, we demonstrated that animals lacking the -y isoform of PKC displayed significantly greater susceptibility to brain damage produced by re versible focal ischemia, and this increase in damage was reversed by an inhibitor of calcineurin, FK506.
We were concerned with the genetic heterogeneity of these animals because strain differences in damage after ischemia have been documented in mice (Barone et aI., 1993; Fujii et aI., 1997) . Our analysis showed different susceptibility to ischemia, although statistically insignifi cant, among BALB/cJ, C57BL/6J, and I 29/SVJ, with BALB/cJ being most vulnerable and 129/SVJ being the least vulnerable. The gradient of strain vulnerability to ischemia was similar to that described in previous work (Barone et aI., 1993; Fujii et aI., 1997) . When we com pared susceptibility of all these mice to that of -yPKC KO, the -yPKC-KO mice displayed significantly greater vulnerability to ischemia, strongly suggesting that the absence of functional -yPKC contributed to the increased damage. This implies that ),PKC plays an as yet unde fined role in protecting neurons after an ischemic insult.
As mentioned earlier, studies on the role of PKC in ischemia have not established its relevance to ischemic damage. Both activation and inactivation of the enzyme by ischemia have been demonstrated, and both protective and detrimental effects of PKC have been postulated (Louis et aI., 1988; Kochhar et aI., 1989; Wieloch et aI., 1991; Aronowski et aI., 1992; Cardell and Wieloch, 1993; Cardell et aI., 1991; Aronowski et aI., 1992b; Sieber et aI., 1998; Hara et aI., 1990; Madden et aI., 1991) . Protein kinase C is ubiquitously distributed throughout a variety of cell types, and in the brain PKC is present in neurons, glia, smooth muscles, endothelial cells, and other cells (Tanaka and Nishizuka, 1994) . Pro tein kinase C consists of a family of at least 12 isoforms, with 4 isoforms (a, �I, �II, and )') that require Ca 2 + for their activation. Each isoform can be activated by a dis tinct subset of second messengers, can be expressed in distinct cell types, and has different intracellular local ization (Tanaka and Nishizuka, 1994; Krizbai et aI., 1995; Van der Zee et aI., 1995; Erbrugger et aI., 1997) . Because each PKC isoform is likely to modulate distinct, potentially opposing functions, it could be misleading to draw conclusions about the role of PKC enzymes based on analysis of their (all isoforms together) generalized activity changes in whole brain. Additionally, com pounds that inhibit all PKC isoform could lead to a dif ferent outcome than the selected loss of one isoform produced by gene knock-out. Cerebrovascular tone has a direct impact on ischemic stroke outcome. Vasoconstriction resulting in reduced CBF can produce augmentation of ischemia and subse quent damage. Recently, activation of vascular PKC was demonstrated to produce vasoconstriction linked to the pathogenesis of cerebral vasospasm (Ohta et aI., 1995) . In addition, inhibition of PKC by the protein kinase in hibitor, staurosporine, was reported to inhibit vascular smooth muscle contractility (Asano et aI., 1995) , provid ing a possible explanation for the protective mechanism of staurosporine in ischemic models (Hara et aI., 1990) . A role for I'PKC in regulating vascular contractility is unknown, and although absent from blood vessels (Mat tila et aI., 1994; Krizbai et aI., 1995; Erdbrugger et aI., 1997) , I'PKC could affect vascular tone through its in nervation. I'PKC is highly enriched in neurons, where it is postulated to regulate synaptic activity or gene expres sion in response to signal activating Ca 2 + entry (Hata et aI., 1993; Abe1iovich et aI., 1993a; Sakai et aI., 1997) . It is, therefore, logical to consider that increased vulner ability to ischemia in I'PKC-KO animals, observed in the current study, results from I'PKC mutation-induced neu ronal dysfunction.
Neuronal PKC, similar to ca1cineurin, is involved in regulation of diverse aspects of signal transduction in cluding neurotransmitter release, receptors, ion channels, enzyme regulation, and gene expression (Klee et aI., 1988; Yakel, 1997; Ryves et aI., 1996; Tanaka and Nishi zuka, 1994) . Ca1cineurin and I'PKC share common sub strates. Some of these include dynamin I, GAP-43, MARCKS, IP 3 receptor, and nitric oxide synthase (Rob inson et aI., 1994; Robinson, 1991; Klee, 1991; Bredt et aI., 1992; Dawson et aI., 1993; Cameron, 1995; Mahoney et aI., 1995) . Deficient substrate phosphorylation by PKC, as that likely present in I'PKC-KO mice, might, therefore, be corrected by inhibiting substrate dephos phorylation, including that by ca1cineurin.
One of the cell-permeable ca1cineurin inhibitors is the immunosuppressant drug FK506 (Liu, 1991) . Similar to the effect of FK506 on infarct volume in I'PKC-KO ani mals, FK506 was shown to protect rat brain from damage after reversible focal ischemia (Sharkey and Butcher, 1994; Butcher et aI., 1997) . This neuroprotective mecha nism of FK506 was postulated to involve inhibition of ca1cineurin with subsequent inhibition of nitric oxide synthase and reduction of cytotoxic NO production (Bredt et aI., 1992; Dawson et aI., 1993) . We find it surprising that the neuroprotective effect of FK506 was significant in I'PKC-KO animals, whereas no effect in BALB/cJ mice was observed. It is generally accepted that the portion of ischemic brain most likely to be sal vaged by therapeutic intervention is the ischemic pen umbra, due to presence of collateral flow resulting in better perfusion than in the infarct core. Because I'PKC KO mice develop larger infarctions, it is possible that J Cereh Blood Flow Metah, Vol. 20, No.2, 2000 this is caused by lesser resistance of the I'PKC mutated neurons to the level of hypoperfusion present in the pen umbral region. The efficacy of FK506 in I'PKC-KO may be linked to the possibility that there is a larger ischemic penumbra in these mice. The dose of FK506 used in the current study is the same as that which is optimal in producing immunosuppression and in protecting brain from focal ischemia in rats (Sharkey and Butcher, 1994) . However, there is a difference in FK506 pharmacokinet ics between rats and mice. The I-mg/kg dose of FK506 used to produce immunosuppression may be suboptimal in mice (Iwata et aI., 1993) , since a three-to five-times larger dose is required to produce optimal immunosup pression and possibly neuroprotection in wild-type mice compared with rats (Bekersky I, personal communica tion, 1998). Because I'PKC-KO mice may have impaired phosphorylation compared with wild-type animals, it is possible that a lower dose of FK506 is sufficient to cor rect deficient phosphorylation produced by the I'PKC mutation.
In summary, I'PKC-deficient mice are more suscep tible to ischemia. This vulnerability may be mediated by imbalances between impaired PKC phosphorylation and unimpaired ca1cineurin-mediated protein dephosphoryla tion in the regulation of neuronal enzymes essential for cell homeostasis and survival.
